newsfilter
← Latest News
Business Wire·

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation